Eton Pharmaceuticals

52 articles with Eton Pharmaceuticals

• Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors

  3/17/2021

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021.

• Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results

  3/16/2021

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on business progress.

• Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16, 2021

  3/4/2021

  Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, announced that it will report fourth quarter and full year 2020 financial and operating results on Tuesday, March 16, 2021.

• Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference

  2/16/2021

  Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10 th Annual SVB Leerink Global Healthcare Conference from February 24 th through February 26 th .

• Azurity Pharmaceuticals Announces Three New Neurology Products

  2/9/2021

   Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today the purchase of the neurology portfolio from Eton Pharmaceuticals. 

• Eton Pharmaceuticals Announces Sale of Neurology Portfolio

  2/8/2021

  Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmaceuticals.

• Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

  1/14/2021

  Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL)

• Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral SolutionApplication Assigned a PDUFA Date of August 6, 2021

  12/17/2020

  Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for topiramate oral solution.

• Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States

  11/24/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the full availability of ALKINDI® SPRINKLE for sale and distribution in the United States.

• Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results

  11/12/2020

  Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, reported financial results for the third quarter ended September 30, 2020 and provided an update on business progress.

• Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020

  11/4/2020

  Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, announced that it will report third quarter 2020 financial and operating results on Thursday, November 12, 2020.

• Eton Pharmaceuticals Announces Closing of Public Offering

  10/16/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. The total offering included 420,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.

• Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension- Application Assigned a PDUFA Date of May 29, 2021

  10/15/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for zonisamide oral suspension. The application has been assigned a Prescription Drug User Fee Act (PDUFA) date of May 29, 2021. The application was s

• Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock

  10/14/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000 shares of its common stock at a price to the public of $7.00 per share, for gross proceeds of $19.6 million. The Company has also granted the underwriters a 45-day option to purchase, at the same price

• Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock

  10/13/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Wednesday, October 14, 2020. Eton Pharmaceuticals intends to use the net proceeds from the offering primarily for general

• Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

  10/8/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for dehydrated alcohol injection

• Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)

  10/6/2020

  - Application Submitted for the Treatment of Partial-Onset Seizures and Migraine - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Topiramate - Topiramate Oral Solution is Eton’s Third Neurology Product Candidate Submitted to the FDA DEER PARK, Ill., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric disea

• Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency

  9/29/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ALKINDI® SPRINKLE (hydrocortisone) oral granules as replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.

• 

  FDA Action Alert: Aquestive, Eton and Mesoblast

  9/28/2020

  The U.S. Food and Drug Administration (FDA) is wrapping up the month of September with a few PDUFA dates. Here’s a look.

• Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs

  8/31/2020

  Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Ingrid Hoos as the company’s new Senior Vice President of Scientific Affairs.